Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Male Hypogonadism – Overview
Male Hypogonadism – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Male Hypogonadism – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Male Hypogonadism – Companies Involved in Therapeutics Development
Allergan Plc
Diurnal Group Plc
EndoCeutics Inc
Ferring International Center SA
Lipocine Inc
M et P Pharma AG
Medlab Clinical Ltd
Merck & Co Inc
Mereo Biopharma Group Plc
TesoRx Pharma LLC
Viramal Ltd
Male Hypogonadism – Drug Profiles
chorionic gonadotropin ER – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corifollitropin alfa – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enclomiphene citrate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IAS-167A – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kisspeptin-10 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leflutrozole – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leuprolide acetate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Libidua – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LPCN-1111 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Block VDAC1 for Hypogonadism – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rifene – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone propionate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VERU-722 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Male Hypogonadism – Dormant Projects
Male Hypogonadism – Discontinued Products
Male Hypogonadism – Product Development Milestones
Featured News & Press Releases
Nov 01, 2019: Acerus provides update on temporary unavailability of NATESTO in Canada and South Korea
Oct 23, 2019: Acerus Pharma hosting key opinion leader meeting on unique clinical evidence of NATESTO for treatment of Hypogonadism
Oct 17, 2019: New data demonstrates that Natesto increases serum testosterone and improves symptoms while maintaining normal semen parameters in men with low testosterone through six months
Oct 16, 2019: Aytu BioScience to announce results from Natesto spermatogenesis study on Thursday, October 17
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Number of Products under Development for Male Hypogonadism, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Male Hypogonadism - Pipeline by Allergan Plc, H2 2019
Male Hypogonadism - Pipeline by Diurnal Group Plc, H2 2019
Male Hypogonadism - Pipeline by EndoCeutics Inc, H2 2019
Male Hypogonadism - Pipeline by Ferring International Center SA, H2 2019
Male Hypogonadism - Pipeline by Lipocine Inc, H2 2019
Male Hypogonadism - Pipeline by M et P Pharma AG, H2 2019
Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H2 2019
Male Hypogonadism - Pipeline by Merck & Co Inc, H2 2019
Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2019
Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H2 2019
Male Hypogonadism - Pipeline by Viramal Ltd, H2 2019
Male Hypogonadism - Dormant Projects, H2 2019
Male Hypogonadism - Discontinued Products, H2 2019
List of Figures
Number of Products under Development for Male Hypogonadism, H2 2019 9
Number of Products under Development by Companies, H2 2019 10
Number of Products by Targets, H2 2019 16
Number of Products by Stage and Targets, H2 2019 16
Number of Products by Mechanism of Actions, H2 2019 18
Number of Products by Stage and Mechanism of Actions, H2 2019 18
Number of Products by Routes of Administration, H2 2019 20
Number of Products by Stage and Routes of Administration, H2 2019 20
Number of Products by Molecule Types, H2 2019 22
Number of Products by Stage and Molecule Types, H2 2019 22
【掲載企業】
Allergan Plc
Diurnal Group Plc
EndoCeutics Inc
Ferring International Center SA
Lipocine Inc
M et P Pharma AG
Medlab Clinical Ltd
Merck & Co Inc
Mereo Biopharma Group Plc
TesoRx Pharma LLC
Viramal Ltd